关闭
 
读者在线:用户名 密码
首页 期刊简介 投稿须知 期刊目录 专家风采 编委会 特邀顾问 联系我们 移动出版
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5



刊物信息

期刊名称:药物分析杂志
主管单位:中国科学技术协会
主办单位:中国药学会
承办:中国食品药品检定研究院
主编:金少鸿
地址:北京天坛西里2号
邮政编码:100050
电话:010-67012819,67058427
电子邮箱:ywfx@nicpbp.org.cn
国际标准刊号:ISSN 0254-1793
国内统一刊号:CN 11-2224/R
邮发代号:2-237
 

访问统计
您是第  3 2 8 4 0 7 5 位浏览者
您当前的位置:首页 >> 正文

二氢吡啶类药物杂质研究概述

Overview and discussion on the impurity investigation for dihydropyridines

作者(英文):
分类号:R917
出版年·卷·期(页码):2018,38 (12):2045-2053
DOI: 10.16155/j.0254-1793.2017.01.01
-----摘要:-------------------------------------------------------------------------------------------

杂质影响药物的稳定性和质量,降低疗效,并带来可能的毒副作用,分析并控制杂质含量对保证药物质量和用药安全十分重要,是新药研发和仿制药质量疗效一致性评价的一项重要内容。本文以临床抗高血压一线用药二氢吡啶类药物为例,讨论了杂质研究所涉及的杂质来源、检测方法、杂质限度以及评价标准等相关内容,并对可能出现的问题提出了解决建议,为药物的杂质研究提供参考。

-----英文摘要:---------------------------------------------------------------------------------------

Pharmaceutical impurities affect the stability and quality of the drug,reduce the efficacy,and even cause adverse effects on the human body. Therefore,the impurity investigation is critical to ensure the quality and effectivity of drugs,and is an important part for the novel drug development and generic product consistency evaluation. In this paper,the impurities of dihydropyridine derivates,as an example,were discussed on the sources,determinations,limits and evaluation criteria. And feasible suggestions were given for potential problems. This paper could provide a reference for impurity studies.

-----参考文献:---------------------------------------------------------------------------------------
[1] 中华人民共和国药典2015年版.四部[S].2015:377 ChP 2015.VolⅣ[S].2015:377
[2] 戚立凯,狄斌.药物杂质研究方法最新进展[J].中国药科大学学报,2015,46(3):257 QI LK,DI B.Advances in research on pharmaceutical impurities[J].J China Pharm Univ,2015,46(3):257
[3] 高丽,沈丽萍,李艳翠.仿制制剂杂质研究及控制方法[J].黑龙江医药科学,2011,34(3):34 GAO L,SHEN LP,LI YC.Impurity research and control method of generic preparation[J].Heilongjiang Med Pharm,2011,34(3):34
[4] 张明媛.三种化学药物中有关物质的分析方法研究[D].上海:第二军医大学,2013 ZHANG MY.Studies on Analytical Methods of Related Substances in 3 Chemical Drugs[D].Shanghai:The Second Military Medical University,2013
[5] 陈震.仿制药有关物质检查研究的常见问题分析[J].中国医药工业杂志,2010,41(4):305 CHEN Z.Analysis of common issues in related substances study of generic drug[J].Chin J Pharm,2010,41(4):305
[6] 杨燕,吴文辉,汤庆伟,等.基于药品采购数据库的上海市各级医疗机构降压药物利用情况分析[J].中国卫生经济,2016,35(9):77 YANG Y,WU WH,TANG QW,et al.Analysis on the antihypertensive drug utilization in medical institutions of Shanghai based on drug bidding database[J].Chin Health Econ,2016,35(9):77
[7] 周斌,吴晓明.心血管系统用药市场现状与发展趋势[J].中国医药工业杂志,2014,45(3):S20 ZHOU B,WU XM.Marketing and development trend of cardiovascular system drugs[J].Chin J Pharm,2014,45(3):S20
[8] 蔡鹏俊,李悦.几种沙坦类药物的杂质谱研究现状[J].药物分析杂志,2016,36(3):377 CAI PJ,LI Y.Research progress of sartans' impurity profile[J].Chin J Pharm Anal,2016(3):377
[9] [H]GPH3-1化学药物杂质研究的技术指导原则[S].2005 [H]GPH3-1 Technical Guidelines for the Study of Chemical Impurities[S].2005
[10] 刘艳.二氢吡啶类药物尼索地平与非洛地平有关物质的研究[D].咸阳:陕西中医学院,2010 LIU Y.The Relevant Material Research of Dihydropyridine Drugs Nisoldipine and Felodipine[D].Xianyang:Shaanxi University of Chinese Medicine,2010
[11] 郭栋,宋嘉熙,李丹,等.手性尼莫地平绝对构型的确定和关联[J].物理化学学报,2016,32(9):2241 GUO D,SONG JX,LI D,et al.Determination and correlation of the absolute configurations of chiral nimodipine[J].Acta Phys Chim Sin.2016,32(9):2241
[12] MARCINIEC B,KOZAK M,OGRODOWCZYK M.DSC study of radiostability of 1,4-dihydropyridine derivatives[J].J Therm Anal Calorim,2004,77(2):581
[13] 张博.尼莫地平欧洲药典杂质合成与生产过程杂质控制[D].济南:山东大学,2012 ZHANG B.The Synthesis of Nimodipine Impurity in EP and the Process Control of Impurity[D].Jinan:Shangdong University,2012
[14] 张亚鲁,张毅,陈建超,等.苯磺酸氨氯地平有关物质的合成与结构确证[J].沈阳药科大学学报,2015,32(3):188 ZHANG YL,ZHANG Y,CHEN JC,et al.Synthesis and structural identification of impurities from amlodipine besylate[J].J Shenyang Pharm Univ,2015,32(3):188
[15] 宋志勇.抗高血压药丁酸氯维地平及其杂质标准品合成工艺研究[D].太原:太原理工大学,2015 SONG ZY.Study on the Synthetic Pricess of Antipertensive Drug Clevidipine Butyrate and Impurity Standards[D].Taiyuan:Taiyuan University of Technology,2015
[16] 褚小琴,闫少杰,李树军,等.丁酸氯维地平降解杂质的合成[J].合成化学,2017(1):80 CHU XQ,YAN SJ,LI SJ,et al.Synthesis of the degradation impurities of clevidipine butyrate[J].Chin J Synth Chem,2017(1):80
[17] JAIN D,BASNIWAL PK.Forced degradation and impurity profiling:Recent trends in analytical perspectives[J].J Pharm Biomed Anal,2013,86:11
[18] [H]GPH4-1化学药物制剂研究基本技术指导原则[S].2005[H]GPH4-1 Basic Technical Guideline for the Study of Chemical Preparations[S].2005
[19] RAIJADA D,CORNETT C,RANTANEN J.A high throughput platform for understanding the influence of excipients on physical and chemical stability[J].Int J Pharm,2013,453(1):285
[20] 吴暎,刘伟,林萍.HPLC法检测苯磺酸氨氯地平片剂中的乳糖相关杂质[J].药学进展,2013,37(2):78 WU Y,LIU W,LIN P.Determination of the lactose-related impurities in amlodipine besylate tablets by HPLC method[J].Prog Pharm Sci,2013,37(2):78
[21] 王淼,陈海珍.焦糖中相关杂质的测定研究[J].中国药品标准,2014,15(4):292 WANG M,CHEN HZ.Study on the determination of impurities in caramel[J].Drug Stand China,2014,15(4):292
[22] 李闻新.新型药用辅料磺丁基醚-β-环糊精的质量控制方法研究[D].石家庄:河北医科大学,2013 LI WX.Studies on Quality Control Methods of a New Excipient Betadex Sulfobutyl Ether Sodium[D].Shijiazhuang:Hebei Medical University,2013
[23] LAPANJA N,ZUPANCIC B,CASAR RT,et al.A generic industry approach to demonstrate efficient purification of potential mutagenic impurities in the synthesis of drug substances[J].Organ Process Res Dev,2015,19(11):1524
[24] MULLER L,MAUTHE RJ,RILEY CM,et al.A rationale for determining,testing,and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity[J].Regul Toxicol Pharmacol,2006,44(3):198
[25] RAMAN NVVSS,REDDY KR,PRASAD AVSS,et al.Development and validation of RP-HPLC method for the determination of genotoxic alkyl benzenesulfonates in amlodipine besylate[J].J Pharm Biomed Anal,2008,48(1):227
[26] 龚心实,张斐,董静,等.LC-MS/MS法检测盐酸鲁拉西酮中磺酸酯基因毒杂质[J].药学与临床研究,2013,21(3):235 GONG XS,ZHANG F,DONG J,et al.Limit test of trace amount of genotoxic substance-sulfonic acid ester in lurasidone hydrochloride by liquid chromatography tandem mass spectrometry[J].Pharm Clin Res,2013,21(3):235
[27] 徐丽,陆晨光.GC-MS法同时检测甲磺酸拉非酰胺中2个磺酸酯基因毒杂质[J].山东化工,2016,45(6):46 XU L,LU CG.Determination of potential carcinogenic and genotoxic sulfonate impurities in ralfinamide mesilate by gas chromatography-mass spectrometer[J].Shandong Chem Ind,2016,45(6):46
[28] International Conference on Harmonisation (ICH) M7 Tripartite Guideline.Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk,Current Step 4 version,23 June[EB/OL].2014[2017-05-01]. http://www.ich.org/products/guidelines/multidisciplinary/article/multidisciplinary-guidelines.html
[29] HOLM R,ELDER DP.Analytical advances in pharmaceutical impurity profiling[J].Eur J Pharm Sci,2016,87:118
[30] 刘雁鸣,龙海燕,彭琳,等.HPLC-DAD法对注射用头孢地嗪钠杂质谱的一致性分析研究[J].中国药品标准,2013,14(3):170 LIU YM,LONG HY,PENG L,et al.Analysis study on consistency of the impurity profiles of cefodizime sodium for injection by HPLC-DAD[J].Drug Stand China,2013,14(3):170
[31] 张明媛,张军东,陆峰.基于杂质谱的仿制药质量一致性评价流程研究[C]//2013中国药学大会暨第十三届中国药师周论文集.2013 ZHANG MY,ZHANG JD,LU F.Evaluation procedure for quality consistency of generic drugs based on the impurity profile[C]//The Collection of the China Pharmaceutical Conference and the 13th Chinese Pharmacist Week.2013
[32] 冯雪松,董鸿晔.中药指纹图谱中的数据挖掘技术[J].药学进展,2002,26(4):198 FENG XS,DONG HY.Data mining in establishing fingerprint spectrum of Chinese traditional medicines[J].Prog Pharm Sci,2002,26(4):198
[33] 吴玲芳,林琛,崔雅萍,等.基于聚类分析和主成分分析的叶下珠多酚部位HPLC指纹图谱研究[J].世界科学技术:中医药现代化,2015(11):2285 WU LF,LIN C,CUI YP,et al.HPLC fingerprint of total phenol in Phyllanthus urinaria L.from different habitats based on cluster analysis coupled with principle component analysis[J].World Sci Technol mod Tradit Chin Med Mater Med,2015(11):2285
[34] 中华人民共和国药典2015年版.二部[S].2015:623 ChP 2015.VolⅡ[S].2015:623
[35] 谢沐风.如何建立TLC测定药物有关物质的方法[J].中国医药工业杂志,2003,34(11):580 XIE MF.How to establish a TLC method for determination of related substances in drugs[J].Chin J Pharm,2003,34(11):580
[36] 陈波.尼伐地平原料药的质量控制研究[D].长沙:中南大学,2013 CHEN B.Studies on the Quality Control of Nilvadipine[D].Changsha:Central South University,2013
[37] 刘艳华,吕狄亚,宋志勇,等.反向高效液相色谱法同时测定丁酸氯维地平中10种相关杂质[J].分析化学,2015,43(2):257 LIU YH,LU DY,SONG ZY,et al.Development and validation of a high performance liquid chromatographic method for simultaneous determination of ten process-related impurities of clevidipine butyrate[J].Chin J Anal Chem,2015,43(2):257
[38] VOJTA J,JEDLICKA A,COUFAL P,et al.A new,rapid,stability-indicating UPLC method for separation and determination of impurities in amlodipine besylate,valsartan and hydrochlorothiazide in their combined tablet dosage form[J].J Pharm Biomed Anal,2015,109:36
[39] LIU DQ,SUN M,WU L.Eliminating pharmaceutical impurities:recent advances in detection techniques[J].Curr Opin Drug Disc Develt,2010,13(6):748
[40] ZHOU YX,FAN Z,FEI Y,et al.Structural analysis and quantitative determination of clevidipine butyrate impurities using an advanced RP-HPLC method[J].J Chromatogr Sci,2015,54(3):3
[41] REDDY GVR,KUMAR AP,REDDY BV,et al.Separation,identification and structural elucidation of a new impurity in the drug substance of amlodipine maleate using LC-MS/MS,NMR and IR[J].Croat Chem Acta,2010,83(4):443
[42] TAYLOR GE,GOSLING M,PEARCE A.Low level determination of p-toluenesulfonate and benzenesulfonate esters in drug substance by high performance liquid chromatography/mass spectrometry[J].J Chromatogr A,2006,1119(1-2):231
[43] KAKADIYA PR,REDDY BP,SINGH V,et al.Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in lopinavir and ritonavir active pharmaceutical ingredients by LC/MS/MS using electrospray ionization[J].J Pharm Biomed Anal,2011,55(2):379
[44] MIELCAREK J,MATLOKA A.Gas chromatography-mass spectrometry identification of photoproducts of hexahydroquinoline derivatives:potential calcium channel antagonists[J].J Chromatogr B,2005,819(1):17
[45] 罗功才.气相色谱法分析尼索地平及其片剂稳定性[J].中国药学杂志,2008,43(21):1671 LUO GC.Gas chromatographic analysis of nisoldipine and the stability of its tablets[J].Chin Pharm J,2008,43(21):1671
[46] 李月秋.毛细管电泳在医药学中的应用[J].黑龙江医药,2008,21(3):31 LI YQ.Applications of capillary electrophoresis in medicine[J].Heilongjiang Med J,2008,21(3):31
[47] 高峰,周亭亭,苑广信.毛细管分析技术的应用与展望[J].中国医药科学,2012,23(2):45 GAO F,ZHOU TT,YUAN GX.Application and prospect of capillary electrophoresis analysis technology[J].China Med Pharm,2012,2(23):45
[48] 孔德志.间尼索地平质量控制与药代动力学研究[D].石家庄:河北医科大学,2010 KONG DZ.Studies on Quality Control and Pharmacokinetics of m-Nisoldipine[D].Shijiazhuang:Hebei Medical University,2010
[49] 张晶,陈晓东,李丽群,等.超临界流体色谱与高效液相色谱分离手性化合物的比较[J].色谱,2016,34(3):321 ZHANG J,CHEN XD,LI LQ,et al.Comparative separation of chiral compounds by supercritical fluid chromatography and high performance liquid chromatography[J].Chin J Chromatogr,2016,34(3):321
[50] 张怡评,洪专,方华,等.超临界流体色谱分离技术应用研究进展[J].中医药导报,2012,18(7):89 ZHANG YP,HONG Z,FANG H,et al.Research progress of supercritical fluid chromatography separation technology[J].Guid J Tradit Chin Med Pharm,2012,18(7):89
[51] SAMOKHIN AS,REVELSKY IA,CHEPELYANSKY DA,et al.Supercritical fluid chromatography and its application to analysis and preparation of high-purity compounds[J].Russ J Phys Chem B,2012,6(7):769
[52] GYLLENHAAL O,KARLSSON A,VESSMAN J.Packed-column supercritical fluid chromatography for the purity analysis of clevidipine,a new dihydropyridine drug[J].J Chromatogr A,1999,862(1):95
[53] 张哲峰,魏农农,鲁爽.浅谈杂质限度制定的一般原则[J].中国新药杂志,2008,17(16):1457 ZHANG ZF,WEI NN,LU S.Common principle in establishing the limitation[J].Chin J New Drugs,2008,17(16):1457
[54] 陈震.有关物质的研究与新药注册[J].中国医药工业杂志,2010,41(11):872 CHEN Z.Study on related substances and new drug application[J].Chin J Pharm,2010,41(11):872
[55] 何伍,王海学.浅谈药物杂质限度的制订方法[J].中国医药工业杂志,2009,40(10):787 HE W,WANG HX.General consideration for validation of impurity limitation in drug development[J].Chin J Pharm,2009,40(10):787
[56] 谢沐风.再谈仿制药研发中杂质研究思路之我见[J].中国医药工业杂志,2015,46(5):538 XIE MF.Re-discussion on the studies of related substances in generic drugs[J].Chin J Pharm,2015,46(5):538

欢迎阅读《药物分析杂志》!您是该文第 246位读者!

药物分析杂志 © 2009
地址:北京天坛西里2号
邮政编码:100050; 技术支持:010-60213898

电子邮件:ywfx@nicpbp.org.cn